Earnings History Data for Y-mAbs Therapeutics, Inc. (YMAB) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Y-mAbs Therapeutics, Inc.

Y-mAbs Therapeutics Inc. is a biopharmaceutical company. It focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The company's product pipeline consists of naxitamab and omburtamab which are in clinical stage. Y-mAbs Therapeutics Inc. is based in NEW YORK, USA.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
29-02-2024	AH		YMAB	Y-mAbs Therapeutics, Inc.	719.76	-0.02	-0.19	0.03	Y-mAbs Therapeutics GAAP EPS of -$0.02 beats by $0.18, revenue of $23.4M beats by $2.45M [2/29/2024 4:24 PM]	18.63	1.93 (11.56%)	20.50	3.80 (22.75%)	2.70 - 20.90	1,118,621	340,000	17,089
Y-mAbs Therapeutics GAAP EPS of -$0.02 beats by $0.18, revenue of $23.4M beats by $2.45M [2/29/2024 4:24 PM] Y-mAbs up 17% after hours on strong 2024 guidance, quarterly beats [2/29/2024 5:41 PM]
13-11-2023	AH		YMAB	Y-mAbs Therapeutics, Inc.	222.46	-0.18	-0.16	-0.63	Y-mAbs Therapeutics GAAP EPS of -$0.18 misses by $0.01, revenue of $20.45M misses by $0.48M [11/13/2023 4:08 PM]	5.29	0.41 (8.40%)	5.35	0.47 (9.63%)	2.70 - 10.95	287,076	180,000	605
Y-mAbs Therapeutics GAAP EPS of -$0.18 misses by $0.01, revenue of $20.45M misses by $0.48M [11/13/2023 4:08 PM]
10-08-2023	AH		YMAB	Y-mAbs Therapeutics, Inc.	250.27	-0.14	-0.24	-0.94	Y-mAbs Therapeutics GAAP EPS of -$0.14 beats by $0.11, revenue of $20.75M beats by $0.4M [8/10/2023 4:10 PM]	5.54	-0.62 (-10.15%)	6.25	0.09 (1.46%)	2.70 - 19.52	209,388	250,000	1,020
Y-mAbs Therapeutics GAAP EPS of -$0.14 beats by $0.11, revenue of $20.75M beats by $0.4M [8/10/2023 4:10 PM]
08-05-2023	AH	4:00 PM ET (May 8)	YMAB	Y-mAbs Therapeutics, Inc.	269.93	-0.15	-0.31	-0.64	Y-mAbs Therapeutics GAAP EPS of -$0.15 beats by $0.17, revenue of $20.25M beats by $4.7M [5/8/2023 4:03 PM]	9.24	2.47 (36.48%)	7.43	0.66 (9.75%)	2.70 - 20.48	1,585,778	260,000	2,354
Y-mAbs Therapeutics GAAP EPS of -$0.15 beats by $0.17, revenue of $20.25M beats by $4.7M [5/8/2023 4:03 PM]
30-03-2023	AH	4:00 PM ET (Mar 30)	YMAB	Y-mAbs Therapeutics, Inc.	169.43	0.03	-0.44	-0.85	Y-mAbs Therapeutics GAAP EPS of -$2.19 beats by $0.46, revenue of $65.27M beats by $11.88M [3/30/2023 4:39 PM]	5.03	1.74 (52.85%)	4.17	0.88 (26.75%)	2.70 - 20.48	18,413,880	310,000	3,204
Y-mAbs Therapeutics GAAP EPS of -$2.19 beats by $0.46, revenue of $65.27M beats by $11.88M [3/30/2023 4:39 PM] Y-mAbs Therapeutics files for $150M mixed shelf offering [3/30/2023 5:59 PM]
07-11-2022	AH	4:05 PM ET (Nov 7)	YMAB	Y-mAbs Therapeutics, Inc.	131.16	-0.63	-0.75	-0.66	Y-mAbs Therapeutics GAAP EPS of -$0.63 beats by $0.07, revenue of $12.5M beats by $0.49M [11/7/2022 4:45 PM]	3.93	0.58 (17.31%)	3.60	0.25 (7.46%)	2.94 - 23.10	1,415,736	1,780,000	2,240
Y-mAbs Therapeutics GAAP EPS of -$0.63 beats by $0.07, revenue of $12.5M beats by $0.49M [11/7/2022 4:45 PM] Y-mAbs Reports Third Quarter 2022 Financial Results and Recent Corporate Developments [Nov-07-22 04:01PM]
08-08-2022	AH	4:00 PM ET (Aug 8)	YMAB	Y-mAbs Therapeutics, Inc.	778.18	-0.94	-0.68	-0.53	Y-mAbs Therapeutics Q2 GAAP EPS, revenue misses, guidance reiterated [8/8/2022 4:08 PM]	17.88	-0.82 (-4.38%)	18.70	0.0 (0.00%)	6.50 - 34.60	373,398	280,000	12,092
Y-mAbs Therapeutics Q2 GAAP EPS, revenue misses, guidance reiterated [8/8/2022 4:08 PM]
09-05-2022	AH	4:00 PM ET (May 9)	YMAB	Y-mAbs Therapeutics, Inc.	408.30	-0.64	-0.71	0.75	Y-mAbs Therapeutics GAAP EPS of -$0.64 beats by $0.08, revenue of $10.49M misses by $0.61M [5/9/2022 4:08 PM]	10.22	2.00 (24.33%)	8.22	0.0 (0.00%)	6.50 - 39.82	539,087	720,715	10,335
Y-mAbs Therapeutics GAAP EPS of -$0.64 beats by $0.08, revenue of $10.49M misses by $0.61M [5/9/2022 4:08 PM] Y-mAbs Announces First Quarter Financial Results and Recent Corporate Developments [May-09-22 04:01PM] YmAbs Therapeutics, Inc. (YMAB) Reports Q1 Loss, Lags Revenue Estimates [May-09-22 05:25PM]
24-02-2022	AH	4:00 PM ET (Feb 24)	YMAB	Y-mAbs Therapeutics, Inc.	344.35	-0.85	-0.71	-0.49	Y-mAbs Therapeutics GAAP EPS of -$1.28 misses by $0.59, revenue of $34.9M beats by $24.08M [2/24/2022 4:13 PM]	8.92	0.91 (11.36%)	8.15	0.14 (1.75%)	6.50 - 39.82	313,601	2,130,000	1,111
Y-mAbs Therapeutics GAAP EPS of -$1.28 misses by $0.59, revenue of $34.9M beats by $24.08M [2/24/2022 4:13 PM] Y-mAbs Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Developments [Feb-24-22 04:01PM] YmAbs Therapeutics, Inc. (YMAB) Reports Q4 Loss, Misses Revenue Estimates [Feb-24-22 05:40PM]
04-11-2021	AH	4:00 PM ET (Nov 4)	YMAB	Y-mAbs Therapeutics, Inc.	1,140	-0.66	-0.60	-0.82	Y-mAbs Therapeutics EPS misses by $0.10, misses on revenue [11/4/2021 4:50 PM]	22.20	-1.53 (-6.45%)	23.57	-0.16 (-0.67%)	22.01 - 55.22	739,311	180,000	293
Y-mAbs Therapeutics EPS misses by $0.10, misses on revenue [11/4/2021 4:50 PM] Y-mAbs Provides Regulatory Update on Omburtamab for the Treatment of Patients with Neuroblastoma CNS/LM Metastasis [Nov-04-21 09:00AM] Y-mAbs Announces Third Quarter Financial Results and Recent Corporate Developments [Nov-04-21 04:05PM] YmAbs Therapeutics, Inc. (YMAB) Reports Q3 Loss, Misses Revenue Estimates [Nov-04-21 06:45PM]
05-08-2021	AH	4:00 PM ET (Aug 5)	YMAB	Y-mAbs Therapeutics, Inc.	1,490	-0.53	-0.68	-1.01	Y-mAbs Therapeutics EPS beats by $0.14, beats on revenue [8/5/2021 4:06 PM]	29.29	-8.02 (-21.50%)	38.00	0.69 (1.85%)	24.77 - 55.22	683,167	220,000	1,526
Y-mAbs Announces Second Quarter Financial Results and Recent Corporate Developments [Aug-05-21 04:01PM] YmAbs Therapeutics, Inc. (YMAB) Reports Q2 Loss, Tops Revenue Estimates [Aug-05-21 06:05PM]
06-05-2021	AH	4:00 PM ET (May 6)	YMAB	Y-mAbs Therapeutics, Inc.	1,220	0.75	0.61	-0.66	Y-mAbs Therapeutics EPS beats by $0.45, misses on revenue [5/6/2021 4:03 PM]	34.20	5.55 (19.37%)	34.20	0.0 (0.00%)	24.77 - 55.22	789,259	260,000	4,548
Y-mAbs Therapeutics EPS beats by $0.45, misses on revenue [5/6/2021 4:03 PM] Y-mAbs surges as BofA upgrades the stock citing Danyelza performance in Q1 [5/7/2021 12:59 PM] Y-mAbs Announces First Quarter Financial Results and Recent Corporate Developments [May-06-21 04:01PM] YmAbs Therapeutics, Inc. (YMAB) Surpasses Q1 Earnings Estimates [May-06-21 05:50PM] Y-mAbs Therapeutics, Inc. to Host Earnings Call [May-07-21 07:15AM]
25-02-2021	AH	4:00 PM ET (Feb 25)	YMAB	Y-mAbs Therapeutics, Inc.	1,550	-0.49	-0.85	-0.60	Y-mAbs Therapeutics EPS beats by $0.19, beats on revenue [2/25/2021 4:57 PM]	35.04	1.36 (4.04%)	33.61	-0.07 (-0.21%)	14.16 - 55.22	381,199	403,640	602
Y-mAbs Therapeutics EPS beats by $0.19, beats on revenue [2/25/2021 4:57 PM]
05-11-2020	AH	4:00 PM ET (Nov 5)	YMAB	Y-mAbs Therapeutics, Inc.	1,830	-0.82	-0.80	-0.70	Y-mAbs Therapeutics EPS in-line [11/5/2020 5:45 PM]	47.31	-1.39 (-2.85%)	48.70	0.0 (0.00%)	14.16 - 50.49	73,859	144,411	1,310